On this page
What each program costs in Louisiana
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 5 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 6 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 7 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 10 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 11 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 12 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 13 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does Louisiana Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Louisiana Medicaid's posted Wegovy criteria cover heart disease or a liver condition and its Zepbound criteria cover sleep apnea, so neither is covered for weight loss alone in those criteria, although a 2026 law requires weight-loss drug coverage upon funding. Read from state documents Nov 6, 2026.
What Louisiana Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Louisiana Department of Health.
WegovyNo
Prior authorization for established cardiovascular disease or MASH, with a patient treatment agreement. Act 898 could change this once funded and criteria are set.
“Established Cardiovascular (CV) Disease (Wegovy Injection or Tablet)”
Louisiana Department of Health · No effective date on the document · read Nov 6, 2026
“Metabolic Dysfunction-Associated Steatohepatitis (MASH) (Wegovy Injection Only)”
Louisiana Department of Health · No effective date on the document · read Nov 6, 2026
ZepboundNo
Prior authorization for moderate to severe sleep apnea in adults with BMI of 30 or more, with a patient treatment agreement. Act 898 could change this once funded and criteria are set.
“The patient has an established diagnosis of moderate to severe obstructive sleep apnea (OSA)”
Louisiana Department of Health · No effective date on the document · read Nov 6, 2026
OzempicNo
Pharmacy claims need a type 2 diabetes diagnosis code.
“Semaglutide – Ozempic®, Rybelsus® Tirzepatide – Mounjaro® Type 2 Diabetes Mellitus E11”
Louisiana Department of Health · No effective date on the document · read Nov 6, 2026
MounjaroNo
Pharmacy claims need a type 2 diabetes diagnosis code.
“Tirzepatide – Mounjaro® Type 2 Diabetes Mellitus E11”
Louisiana Department of Health · No effective date on the document · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Louisiana Department of Health documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
- Jun 9, 2026 · Policy changeAct 898 requires Medicaid coverage of FDA-approved weight loss medications for recipients who meet department criteria. It is effective June 9, 2026 and upon appropriation of funds.
“Effective June 9, 2026 and upon appropriation of funds by the legislature.”
Louisiana Legislature, Act 898 resume digest · No effective date on the document · read Nov 6, 2026
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
2,184 prescriptions
Ozempic and Mounjaro, 2025
204,505 prescriptions
Neighbours covering weight loss
1 of 3
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Louisiana Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Louisiana Medicaid as "not covered" for GLP-1s for obesity under fee-for-service. Louisiana Medicaid covers one or more older weight-loss drugs, but no GLP-1.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Louisiana Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Louisiana Medicaid pay for?
230,117 GLP-1 prescriptions in 2025, 13th of the 50 states and DC, with $222.6 million reimbursed before rebates. Counting the share other payers covered, $230.8 million.
Prescriptions, 2025
230,117
13th of 51
Medicaid paid
$222.6M
13th of 51, before rebates
Per prescription
$967
$1,051 nationally
Weight-loss brands
0.9%
39th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Louisiana is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 0.9% of Louisiana Medicaid's GLP-1 prescriptions in 2025 (2,184). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Mounjaro was Louisiana Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Mounjaro | 103,442 | 45% | $103.2 million | $998 |
| Ozempic | 101,063 | 44% | $95.2 million | $942 |
| Trulicity | 18,718 | 8.1% | $17.4 million | $929 |
| Rybelsus | 3,636 | 1.6% | $3.5 million | $961 |
| Wegovyapproved for weight management | 2,074 | 0.9% | $2.7 million | $1,281 |
| Liraglutide (generic) | 928 | 0.4% | $425,283 | $458 |
| Victoza | 119 | 0.1% | $74,922 | $630 |
| Zepboundapproved for weight management | 110 | 0.0% | $110,831 | $1,008 |
| Bydureon | 27 | 0.0% | $21,009 | $778 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Louisiana?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Louisiana and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
1 of the 3 states next to Louisiana covers GLP-1s for weight loss through Medicaid: Mississippi. None has a lower cash floor than Louisiana's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Louisiana | Not covered | 13 | $39/mo |
| Arkansas | Not covered | 16 | $39/moWellmedr |
| Mississippi | Covered | 15 | $39/moWellmedr |
| Texas | Not covered | 19 | $39/moWellmedr |
















